サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795179

トラベルワクチンの世界市場

Travel Vaccines

出版日
ページ情報
英文 281 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
トラベルワクチンの世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 281 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トラベルワクチンの世界市場は2030年までに188億米ドルに達する見込み

2024年に132億米ドルと推定されるトラベルワクチンの世界市場は、2024～2030年の分析期間にCAGR 6.0%で成長し、2030年には188億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるインフルエンザワクチンは、CAGR 5.5%を記録し、分析期間終了時には94億米ドルに達すると予測されます。ジフテリアワクチン分野の成長率は、分析期間中CAGR 4.9%と推定されます。

米国市場は36億米ドル、中国はCAGR 9.4％で成長すると予測

米国のトラベルワクチン市場は、2024年には36億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに38億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.9％と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

世界のトラベルワクチン市場- 主要動向と促進要因のまとめ

なぜトラベルワクチンは国際的な移動の必須条件となりつつあるのか？

トラベルワクチンは、国際的な移動が容易になればなるほど感染症伝播のリスクも高まる世界化した世界において、重要な安全装置として台頭してきました。黄熱病、A型およびB型肝炎、腸チフス、狂犬病、コレラ、日本脳炎の予防接種は、特定の国を訪れる旅行者に推奨されているだけでなく、しばしば義務付けられています。これらの予防接種は、旅行者と受入国の人々を同様に保護し、世界の疾病の封じ込めに不可欠な公衆衛生の手段として機能しています。

COVID-19パンデミック後の意識の高まりにより、渡航前の診察や予防接種計画の実施率は大幅に上昇しました。各国政府が国境を越えた健康チェックを強化するにつれ、旅行者は予防接種スケジュールを遵守するようになりました。多国間の保健機関や旅行医療クリニックはガイドラインを強化しており、特にアフリカ、アジア、ラテンアメリカのリスクの高い地域では、旅行者の準備態勢を検証するためのデジタルワクチン認証システムが導入されています。

技術や製剤の進歩は、ワクチン接種をどのように促進しているのか？

mRNAプラットフォーム、耐熱性製剤、混合ワクチンなど、ワクチン学分野では大きな技術革新が進んでいます。これらの進歩は、コールドチェーンへの依存を減らし、保存期間を延ばし、投与スケジュールを簡素化します。トラベルワクチンの中には、1回の接種で済むものや経口投与が可能なものもあり、コンプライアンスや利用しやすさが向上しています。

もう一つの主な開発は、電子カルテとモバイルアプリの統合です。これらのアプリは、リマインダーを自動化し、渡航先特有のリスクに基づいたガイダンスを提供します。クリニックは、オーダーメイドのワクチン計画やデジタル証明書をバンドルしたパッケージを提供しています。さらに、プレフィルドシリンジ、マイクロニードルパッチ、経鼻製剤は、特に小児や高齢者層に対する投与の安全性と効率を高めています。

需要を促進している旅行者層と目的地は？

高リスク地域への旅行者、人道支援活動家、留学生、出張者がトラベルワクチンの主要な消費者です。エコツーリズム、農村観光、冒険旅行の急増により、媒介感染症や人獣共通感染症にさらされる機会が増え、ワクチン接種のニーズが高まっています。さらに、新興市場への企業出張や世界・サプライチェーンの拡大により、企業が資金を提供する予防接種プログラムが増加しています。

また、デジタルノマド、宣教師、海外駐在員など、長期または複数回のブースター接種を必要とする非伝統的な旅行者の需要も高まっています。渡航先特有の健康リスクや流行警報により、ワクチン要件が頻繁に変更されるため、旅行クリニックでは直前になって需要が急増します。さらに、国の義務や健康勧告は、ワクチンの入手可能性と旅行者のコンプライアンスに影響を与え続けています。

トラベルワクチン市場の成長はいくつかの要因によって牽引される...

世界の旅行者数の増加、地域特有の疾病リスクに対する意識の高まり、国境を越えた健康プロトコルの厳格化などが成長の主な要因です。mRNA、コンジュゲート、リコンビナント技術を含むワクチンプラットフォームの進歩は、トラベルワクチンの利用可能性と有効性を高めています。アドベンチャー、エコツーリズム、オフグリッド旅行の増加により、病原体への曝露が高い地域への旅行者が増加し、先制予防接種が必要となっています。デジタルヘルスツールやモバイルワクチンパスポートシステムは、渡航前のコンプライアンスを合理化し、より一貫した摂取を促しています。さらに、政府や国際保健機関による制度的支援や、労働力保護に関する民間セクターの取り組みが、市場の勢いをさらに加速させています。

セグメント

疾病タイプ（インフルエンザワクチン、ジフテリアワクチン、肝炎ワクチン、腸チフス・その他ワクチン）、エンドユーザー（成人、小児）

調査対象企業の例

  • Abbott Laboratories
  • ALK-Abello A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • CSL Limited
  • F.？Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals（J&J）
  • Merck & Co., Inc.
  • Moderna Inc.（if included）
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi S.A.
  • Valneva SE

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38249

Global Travel Vaccines Market to Reach US$18.8 Billion by 2030

The global market for Travel Vaccines estimated at US$13.2 Billion in the year 2024, is expected to reach US$18.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Influenza Vaccines, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.4 Billion by the end of the analysis period. Growth in the Diphtheria Vaccines segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 9.4% CAGR

The Travel Vaccines market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Travel Vaccines Market - Key Trends & Drivers Summarized

Why Are Travel Vaccines Becoming a Prerequisite for International Mobility?

Travel vaccines have emerged as vital safeguards in a globalized world, where the ease of international movement also raises the risk of infectious disease transmission. Vaccines for yellow fever, hepatitis A and B, typhoid, rabies, cholera, and Japanese encephalitis are not only recommended but often mandatory for travelers visiting specific countries. These immunizations protect travelers and host populations alike, acting as essential public health tools in global disease containment.

Heightened awareness following the COVID-19 pandemic has significantly increased the uptake of pre-travel medical consultations and vaccination plans. As governments tighten cross-border health checks, travelers are more willing to comply with immunization schedules. Multilateral health bodies and travel medicine clinics are reinforcing guidelines, and digital vaccine certification systems have been deployed to validate traveler readiness, particularly in higher-risk regions of Africa, Asia, and Latin America.

How Are Technological and Formulation Advances Enhancing Vaccine Uptake?

The field of vaccinology is undergoing significant innovation, with mRNA platforms, thermostable formulations, and combination vaccines being tailored for travel use. These advances are reducing cold chain dependency, extending shelf life, and simplifying dosage schedules-key benefits for last-minute or remote-area travelers. Some travel vaccines now require just one dose or offer oral options, improving compliance and accessibility.

Another key development is the integration of electronic health records and mobile apps that automate reminders and provide guidance based on destination-specific risks. Clinics are offering bundled packages with tailored vaccine plans and digital certificates. Additionally, prefilled syringes, microneedle patches, and intranasal formulations are enhancing administration safety and efficiency, particularly for pediatric and elderly populations.

Which Traveler Segments and Destinations Are Fueling Demand?

Tourists, humanitarian workers, international students, and business travelers to high-risk regions are primary consumers of travel vaccines. The surge in eco-tourism, rural tourism, and adventure travel increases exposure to vector-borne diseases and zoonoses, driving vaccination needs. Additionally, corporate travel to emerging markets and global supply chain expansion has led to a rise in enterprise-funded immunization programs.

The demand is also rising in non-traditional traveler categories such as digital nomads, missionaries, and expatriates, who require long-term or multiple booster doses. Destination-specific health risks and outbreak alerts frequently alter vaccine requirements, prompting last-minute surges in demand at travel clinics. Furthermore, national mandates and health advisories continue to influence both vaccine availability and traveler compliance.

The Growth in the Travel Vaccines Market Is Driven by Several Factors…

Expansion in global travel volumes, heightened awareness of region-specific disease risks, and stricter cross-border health protocols are key growth enablers. Advancements in vaccine platforms-including mRNA, conjugate, and recombinant technologies-are increasing the availability and efficacy of travel vaccines. The rise in adventure, eco-tourism, and off-grid travel is pushing more travelers into regions with higher pathogen exposure, necessitating preemptive immunization. Digital health tools and mobile vaccine passport systems are streamlining pre-travel compliance, encouraging more consistent uptake. Additionally, institutional support from governments and global health organizations, alongside private sector initiatives in workforce protection, are further accelerating market momentum.

SCOPE OF STUDY:

The report analyzes the Travel Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines, Typhoid & Other Vaccines); End-Use (Adult End-Use, Pediatric End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • ALK-Abello A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • CSL Limited
  • F.?Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals (J&J)
  • Merck & Co., Inc.
  • Moderna Inc. (if included)
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi S.A.
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Travel Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising International Travel and Cross-Border Movement Drives Demand for Pre-Travel Vaccinations
    • Increased Awareness of Endemic Disease Risks in Emerging Destinations Fuels Preventive Vaccine Uptake
    • Growth in Business, Educational, and Medical Tourism Supports Volume Demand
    • Expanded Inclusion of Yellow Fever, Typhoid, Hepatitis, and Meningococcal Vaccines in Pre-Travel Protocols
    • Regulatory Requirements for Entry Into Certain Countries Drive Compliance-Driven Vaccine Demand
    • Use of Combination and Single-Dose Formulations Improves Convenience and Reduces Missed Doses
    • Growth in Private Clinics and Travel Health Centers Enhances Access to Targeted Immunizations
    • Increased Awareness Campaigns by Health Ministries and Airlines Support Preventive Measures
    • Seasonal Travel Peaks Correlate With Vaccine Appointment Upticks in Urban Markets
    • Availability of Pre-Filled Syringes and Multi-Dose Packs Improves Distribution Efficiency
    • Travel Health App Integrations Support Vaccine Reminders and Record Management
    • Adoption in Backpacking, Volunteer, and High-Risk Travel Segments Sustains Niche Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Travel Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Travel Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Diphtheria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatitis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatitis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Typhoid & Other Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Typhoid & Other Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Typhoid & Other Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adult End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adult End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Adult End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pediatric End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pediatric End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pediatric End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Travel Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Travel Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Travel Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Travel Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION